208 related articles for article (PubMed ID: 28697789)
1. Improvement in asymmetric dimethylarginine and oxidative stress in patients with limb salvage after autologous mononuclear stem cell application for critical limb ischemia.
Madaric J; Valachovicova M; Paulis L; Pribojova J; Mateova R; Sebekova K; Postulkova L; Madaricova T; Bucova M; Mistrik M; Vulev I
Stem Cell Res Ther; 2017 Jul; 8(1):165. PubMed ID: 28697789
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia.
Madaric J; Klepanec A; Valachovicova M; Mistrik M; Bucova M; Olejarova I; Necpal R; Madaricova T; Paulis L; Vulev I
Stem Cell Res Ther; 2016 Aug; 7(1):116. PubMed ID: 27530339
[TBL] [Abstract][Full Text] [Related]
3. No difference in intra-arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia.
Klepanec A; Mistrik M; Altaner C; Valachovicova M; Olejarova I; Slysko R; Balazs T; Urlandova T; Hladikova D; Liska B; Tomka J; Vulev I; Madaric J
Cell Transplant; 2012; 21(9):1909-18. PubMed ID: 22472173
[TBL] [Abstract][Full Text] [Related]
4. Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience.
Subrammaniyan R; Amalorpavanathan J; Shankar R; Rajkumar M; Baskar S; Manjunath SR; Senthilkumar R; Murugan P; Srinivasan VR; Abraham S
Cytotherapy; 2011 Sep; 13(8):993-9. PubMed ID: 21671823
[TBL] [Abstract][Full Text] [Related]
5. Autologous bone marrow mononuclear cell therapy improves symptoms in patients with end-stage peripheral arterial disease and reduces inflammation-associated parameters.
Malyar NM; Radtke S; Malyar K; Arjumand J; Horn PA; Kröger K; Freisinger E; Reinecke H; Giebel B; Brock FE
Cytotherapy; 2014 Sep; 16(9):1270-9. PubMed ID: 24972744
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of granulocyte-colony-stimulating factor administration following autologous intramuscular implantation of bone marrow mononuclear cells: a randomized controlled trial in patients with advanced lower limb ischemia.
Zafarghandi MR; Ravari H; Aghdami N; Namiri M; Moazzami K; Taghiabadi E; Fazel A; Pournasr B; Farrokhi A; Sharifian RA; Salimi J; Moini M; Baharvand H
Cytotherapy; 2010 Oct; 12(6):783-91. PubMed ID: 20078390
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients With Critical Limb Ischemia - The SCELTA Trial.
Liotta F; Annunziato F; Castellani S; Boddi M; Alterini B; Castellini G; Mazzanti B; Cosmi L; Acquafresca M; Bartalesi F; Dilaghi B; Dorigo W; Graziani G; Bartolozzi B; Bellandi G; Carli G; Bartoloni A; Fargion A; Fassio F; Fontanari P; Landini G; Lucente EAM; Michelagnoli S; Orsi Battaglini C; Panigada G; Pigozzi C; Querci V; Santarlasci V; Parronchi P; Troisi N; Baggiore C; Romagnani P; Mannucci E; Saccardi R; Pratesi C; Gensini G; Romagnani S; Maggi E
Circ J; 2018 May; 82(6):1688-1698. PubMed ID: 29576595
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin Treatment Significantly Increased the Concentration of Bone Marrow-Derived Mononuclear Cells and Transcutaneous Oxygen Pressure and Lowered the Pain Scale after Bone Marrow Cells Treatment in Patients with "No-Option" Critical Limb Ischaemia.
Kyselovic J; Adamičková A; Gažová A; Valášková S; Chomaničová N; Červenák Z; Madaric J
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672276
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Autologous Cell-based Therapy in Patients with No-option Critical Limb Ischaemia: A Meta-Analysis.
Wahid FSA; Ismail NA; Wan Jamaludin WF; Muhamad NA; Mohamad Idris MA; Lai NM
Curr Stem Cell Res Ther; 2018; 13(4):265-283. PubMed ID: 29532760
[TBL] [Abstract][Full Text] [Related]
10. Impact of Therapeutic Angiogenesis Using Autologous Bone Marrow-Derived Mononuclear Cells Implantation in Critical Limb Ischemia With Scleroderma - Subanalysis of the Long-Term Clinical Outcomes Survey.
Shoji K; Yanishi K; Yoshimi R; Hamada N; Kondo K; Fujimoto K; Nakajima H; Kuwahara K; Higashi Y; Fukumoto Y; Murohara T; Matoba S;
Circ J; 2019 Feb; 83(3):662-671. PubMed ID: 30726805
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, interacts with gastric oxidative metabolism and enhances stress-induced gastric lesions.
Kwiecien S; Ptak-Belowska A; Krzysiek-Maczka G; Targosz A; Jasnos K; Magierowski M; Szczyrk U; Brzozowski B; Konturek SJ; Konturek PC; Brzozowski T
J Physiol Pharmacol; 2012 Oct; 63(5):515-24. PubMed ID: 23211305
[TBL] [Abstract][Full Text] [Related]
12. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
Trocha M; Merwid-Ląd A; Chlebda-Sieragowska E; Szuba A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A; Sozański T
Exp Gerontol; 2014 Feb; 50():45-51. PubMed ID: 24269305
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and predictors of patients with critical limb ischemia who responded to autologous mononuclear cell transplantation for therapeutic angiogenesis.
Aoyama N; Nishinari M; Ohtani S; Kanai A; Noda C; Hirata M; Miyamoto A; Watanabe M; Minamino T; Izumi T; Ako J
Heart Vessels; 2017 Sep; 32(9):1099-1108. PubMed ID: 28357515
[TBL] [Abstract][Full Text] [Related]
14. Early endothelial progenitor cells in bone marrow are a biomarker of cell therapy success in patients with critical limb ischemia.
Smadja DM; Duong-van-Huyen JP; Dal Cortivo L; Blanchard A; Bruneval P; Emmerich J; Gaussem P
Cytotherapy; 2012 Feb; 14(2):232-9. PubMed ID: 22040109
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Clinical Outcomes Survey of Bone Marrow-Derived Cell Therapy in Critical Limb Ischemia in Japan.
Kondo K; Yanishi K; Hayashida R; Shintani S; Shibata R; Murotani K; Ando M; Mizuno M; Fujiwara T; Murohara T; Matoba S;
Circ J; 2018 Mar; 82(4):1168-1178. PubMed ID: 29386474
[TBL] [Abstract][Full Text] [Related]
16. Relationship between cell number and clinical outcomes of autologous bone-marrow mononuclear cell implantation in critical limb ischemia.
Yusoff FM; Kajikawa M; Takaeko Y; Kishimoto S; Hashimoto H; Maruhashi T; Nakashima A; Wahid SFSA; Higashi Y
Sci Rep; 2020 Nov; 10(1):19891. PubMed ID: 33199760
[TBL] [Abstract][Full Text] [Related]
17. Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products.
Tournois C; Pignon B; Sevestre MA; Al-Rifai R; Creuza V; Poitevin G; François C; Nguyen P
Cytotherapy; 2017 Feb; 19(2):299-310. PubMed ID: 27914820
[TBL] [Abstract][Full Text] [Related]
18. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine.
Thum T; Tsikas D; Stein S; Schultheiss M; Eigenthaler M; Anker SD; Poole-Wilson PA; Ertl G; Bauersachs J
J Am Coll Cardiol; 2005 Nov; 46(9):1693-701. PubMed ID: 16256870
[TBL] [Abstract][Full Text] [Related]
19. Characterization and comparison of bone marrow and peripheral blood mononuclear cells used for cellular therapy in critical leg ischaemia: towards a new cellular product.
Capiod JC; Tournois C; Vitry F; Sevestre MA; Daliphard S; Reix T; Nguyen P; Lefrère JJ; Pignon B
Vox Sang; 2009 Apr; 96(3):256-65. PubMed ID: 19207166
[TBL] [Abstract][Full Text] [Related]
20. Autologous bone-marrow mononuclear cell implantation in patients with severe lower limb ischaemia: a comparison of using blood cell separator and Ficoll density gradient centrifugation.
Hernández P; Cortina L; Artaza H; Pol N; Lam RM; Dorticós E; Macías C; Hernández C; del Valle L; Blanco A; Martínez A; Díaz F
Atherosclerosis; 2007 Oct; 194(2):e52-6. PubMed ID: 16982058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
